Olema Oncology to Participate in Upcoming Investor Conferences
06 Setembro 2023 - 5:30PM
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for women’s cancers, today announced that the Company will present
at the following upcoming investor conferences in September:
- Sean P. Bohen, M.D., Ph.D.,
President and Chief Executive Officer, will participate in a
Fireside Chat at the Morgan Stanley 21st Annual Global
Healthcare Conference in New York on Monday, September 11,
2023, at 10:40 a.m. ET.
- Dr. Bohen will participate in a
Fireside Chat at the H.C. Wainwright 25th Annual Global
Investment Conference in New York on Tuesday, September
12, 2023, at 10:30 a.m. ET.
- Dr. Bohen will participate in a
Fireside Chat at the 2023 Cantor Global Healthcare
Conference in New York on Wednesday, September 27, 2023,
at 4:10 p.m. ET.
A live webcast of the Fireside Chats and any accompanying
presentation materials will be available under the News &
Events section of Olema’s investor relations website at
www.olema.com. The webcasts will be archived for at least 30
days.
About Olema OncologyOlema Oncology is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of targeted therapies for women’s
cancers. Olema’s lead product candidate, palazestrant (OP-1250), is
a proprietary, orally-available small molecule with dual activity
as both a complete estrogen receptor (ER) antagonist (CERAN) and a
selective ER degrader (SERD). It is currently being evaluated both
as a single agent in an ongoing Phase 2 clinical trial, and in
combination with CDK4/6 inhibitors (palbociclib and ribociclib) and
a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally
advanced or metastatic ER-positive (ER+), human epidermal growth
factor receptor 2-negative (HER2-) breast cancer. Palazestrant has
been granted FDA Fast Track designation for the treatment of
ER+/HER2- metastatic breast cancer that has progressed following
one or more lines of endocrine therapy with at least one line given
in combination with a CDK4/6 inhibitor. Olema is headquartered in
San Francisco and has operations in Cambridge, Massachusetts. For
more information, please visit us at www.olema.com, or follow us on
Twitter and LinkedIn.
Contact:Geoffrey Mogilner, Vice President, Investor Relations
and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024